Morpholino-peptide conjugates for DMD - in vitro predicts in vivo
Page 1 of 1
Morpholino-peptide conjugates for DMD - in vitro predicts in vivo
Wang Q, Yin H, Camelliti P, Betts C, Moulton H, Lee H, Saleh AF, Gait MJ, Wood MJ. In vitro evaluation of novel antisense oligonucleotides is predictive of in vivo exon skipping activity for Duchenne muscular dystrophy. J Gene Med. 2010 Mar 16. [Epub ahead of print]
Similar topics
» Quantitative correlation of in vivo properties with in vitro assay results - the in vitro binding of a biotin-DNA analog modifier with streptavidin predicts the in vivo avidin-induced clearability of the analog-modified antibody
» Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody
» Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo
» Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
» Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry
» Quantitative Correlation of in Vivo Properties with in Vitro Assay Results: The in Vitro Binding of a Biotin-DNA Analogue Modifier with Streptavidin Predicts the in Vivo Avidin-Induced Clearability of the Analogue-Modified Antibody
» Peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) restores carbapenem susceptibility to NDM-1-positive pathogens in vitro and in vivo
» Context Dependent Effects of Chimeric Peptide Morpholino Conjugates Contribute to Dystrophin Exon-skipping Efficiency
» Development of a general methodology for labelling peptide-morpholino oligonucleotide conjugates using alkyne-azide click chemistry
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum